symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TSVT,4.11,0,1443582,207409506,0,3.01-17.56,-0.18,"2seventy bio, Inc.",USD,0001860782,US9013841070,901384107,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.2seventybio.com,"2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.",Mr. Nick  Leschly,Healthcare,US,425,339 499 9300,60 Binney Street,Cambridge,MA,02142,,0,https://financialmodelingprep.com/image-stock/TSVT.png,2021-11-03,False,False,True,False,False
